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Abstract
Purpose Anthracyclines remain a cornerstone in the treatment of primary and advanced breast cancer (BC). This study has 
evaluated the predictive value of a multigene mRNA-based drug response predictor (DRP) in the treatment of advanced BC 
with epirubicin. The DRP is a mathematical method combining in vitro sensitivity and gene expression with clinical genetic 
information from > 3000 clinical tumor samples.
Methods From a DBCG cohort, 140 consecutive patients were treated with epirubicin between May 1997 and November 
2016. After patient informed consent, mRNA was isolated from archival formalin-fixed paraffin-embedded primary breast 
tumor tissue and analyzed using Affymetrix arrays. Using time to progression (TTP) as primary endpoint, the efficacy of 
epirubicin was analyzed according to DRP combined with clinicopathological data collected retrospectively from patients’ 
medical records. Statistical analysis was done using Cox proportional hazards model stratified by treatment line.
Results Median TTP was 9.3 months. The DRP was significantly associated to TTP (P = 0.03). The hazard ratio for DRP 
scores differing by 50 percentage points was 0.55 (95% CI –0.93, one-sided). A 75% DRP was associated with a median 
TTP of 13 months compared to 7 months following a 25% DRP. Multivariate analysis showed that DRP was independent 
of age and number of metastases.
Conclusion The current study prospectively validates the predictive capability of DRP regarding epirubicin previously shown 
retrospectively allowing the patients predicted to be poor responders to choose more effective alternatives. Randomized 
prospective studies are needed to demonstrate if such an approach will lead to increased overall survival.
Keywords Epirubicin · Advanced breast cancer · Precision medicine · Predictive biomarker
Introduction
Breast cancer (BC) is one of the most common cancers 
worldwide and accounts for 15% of all cancer-related deaths 
among females [1]. Close to 20% of patients experience 
recurrence either as loco-regional or distant disease [2] in 
addition to the < 10% having primary advanced disease at 
the time of diagnosis [3]. Most of these patients are con-
sidered non-curable and treatment is limited to a palliative 
focus [3].
Anthracyclines, e.g., epirubicin, doxorubicin, and 
pegylated doxorubicin, are widely used in the different set-
tings of BC treatment, and are in the (neo)adjuvant setting 
considered standard treatment [4]. In addition, anthracy-
clines are recommended in locally advanced or metastatic 
disease [5]. Doxorubicin is commonly used in the US, 
whereas the use of epirubicin is more widespread in Europe 
[6]. Epirubicin and doxorubicin are molecular alike with 
similar efficacy although epirubicin potentially has a better 
toxicity profile particular concerning cardiotoxicity [7].
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Despite an increasing number of effective anticancer 
treatments, drug resistance is still a major concern result-
ing in treatment failure [8]. The efficacy of anthracyclines 
appears highly variable with response rates of 42–79% [9, 
10]. Evidently a large proportion of patients do not obtain 
any benefit from the treatment but nonetheless experience 
adverse effects, and furthermore, initiation of a more effec-
tive treatment is delayed. When first-line treatment fails, it 
is well known that the benefit of second-line treatment and 
beyond becomes even more challenging [3, 11]. Systems to 
match a patient and a drug are eagerly awaited [12]. Thus, 
preferably each patients’ tumor should be evaluated in order 
to identify drugs most likely to have an effect in the indi-
vidual patient.
Medical Prognosis Institute has invented a cell line and 
multigene mRNA-based Drug Response Predictor (DRP) 
which is based on drug-specific genetic response profiles 
and evaluates a specific tumor’s potential response to a drug. 
The DRP algorithm is based on cell line data from National 
Cancer Institute (NCI) 60 cell line panel [13]. Available data 
include gene expressions from untreated cell lines. Like-
wise, GI50 values (drug dose that result in 50% reduction 
in growth) are present for different drugs and are regarded 
as measures of cell line sensitivity. In this way, sensitiv-
ity and resistance patterns from cell lines treated with the 
particular drug in vitro are available in a public domain. 
Gene expression from the untreated cell lines is correlated 
to the sensitivity pattern of the drug to show which genes 
are correlated to sensitivity and which genes are correlated 
to resistance in vitro. In order to only include the clinical 
relevant pathways, gene expressions from more than 3000 
patients’ tumors of different origins are compared to the 
raw DRP. Gene expression that was not participating in any 
meaningful biological pathway is excluded from the final 
DRP. This method has increased the signal-to-noise ratio 
and is explained visually in Fig. 1.
The DRP has shown promise in several cancer diseases, 
drugs, and drug combinations and has been retrospectively 
validated in several settings [14–16]. Epirubicin as neoad-
juvant monotherapy has been evaluated retrospectively by 
the predictor in 120 patients with early BC [17]. Further, as 
part of R-CHOP regime, doxorubicin has been validated in 
Diffuse Large B-Cell Lymphoma with the DRP using micro-
RNA [18]. The aim of the current study was to evaluate the 
DRP among epirubicin-treated advanced BC patients.
Methods
Study design and patients
The current epirubicin cohort was identified among patients 
who were screened for participation in a phase 1 trial with 
liposomal cisplatin (LiPlaCis) [19].
Fig. 1  The principle behind the drug response prediction method
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A total of 1199 consecutive patients with locally advanced 
or metastatic BC were enrolled for screening in the LiPlaCis 
cohort. Inclusion criteria were patients with age ≥ 18 years 
with histological confirmed locally advanced or metastatic 
adenocarcinoma of the breast, expected life time ≥ 3 months, 
ECOG performance status (PS) ≤ 2, and written informed 
consent. Exclusion criteria were patients with other pri-
mary malignancy within the last 5 years prior to enrolment, 
except for adequately treated carcinoma in situ of the cervix, 
squamous carcinoma of the skin, or adequately controlled 
limited basal cell skin cancer. Patients were also excluded 
if they had any other disease or physiological dysfunction 
giving reasonable suspicion of a disease or condition that 
contraindicated the use of the investigational drug or place 
the patient at high risk from treatment-related complications. 
Tumor tissue was requested from the local pathology depart-
ment and sent to the Coordinating Department of Pathology, 
Herlev and Gentofte Hospital where a subsample with high 
tumor cell content was selected prior to DRP analysis.
The participating sites were oncology departments at 10 
Danish hospitals (Herlev and Gentofte, Herning, Hilleroed, 
Naestved, Rigshospitalet, Roskilde, Soenderborg, Vejle, 
Aalborg and Aarhus).
The study commenced in March 2013 and is ongoing.
Epirubicin prediction study
Data from all patients enrolled in the LiPlaCis study between 
April 2013 and November 2016 were obtained. Patients 
from the LiPlaCis cohort with a DRP score available and 
who received epirubicin as monotherapy in the advanced 
setting were identified for this study. Inclusion and exclusion 
flowchart are given in Fig. 2.
Clinical data were extracted retrospectively from patients’ 
medical and pathology records including information about 
primary tumor, metastases, and all treatments received in 
the adjuvant and advanced setting. Further, information 
regarding reason to change treatment was defined as either 
progression of disease, toxicity, long-lasting stable disease, 
physician or patient decision. The REMARK guidelines 
were followed where applicable [20].
The patients were followed by radiological assessment 
and clinical examination every 3–4 months, though a few 
patients had clinical progression and shifted treatment with-
out radiological verification. Epirubicin was given as single-
agent chemotherapy to all included patients.
Ethical approval
The LiPlaCis study (ID H-1-2013-016) and this substudy 
(ID HGH-2016-097) were approved by The Regional 
Committee on Health Research Ethics. All patients gave 
informed consent. Data in this substudy were collected in a 
retrospective manner and hence there were no health risks 
associated with the use of data. This was a non-interven-
tion study and the results would not affect future treatment 
of the patients.
Fig. 2  Flowchart of inclusion and exclusion
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Epirubicin sensitivity predictor (Epirubicin DRP) 
development
The in vitro-based method to develop a predictor of drug 
response has been described previously [14–18]. Briefly, it 
is an algorithm based on growth inhibition values (GI50) of 
the NCI60 cell lines [13] subjected to treatment with epi-
rubicin. Gene expression measurements were performed 
with an Affymetrix HG-U133A array (Thermo Fisher Sci-
entific, Waltham, MA, USA). After logit normalization, 
genes with a Pearson’s correlation coefficient to GI50 above 
0.25 or below–0.25 were considered as potential biomark-
ers of sensitivity and resistance, respectively, to treatment 
and retained to contribute to the profile for epirubicin. 425 
genes were correlated to sensitivity and 438 were correlated 
to resistance. To sort away genes only active in the in vitro 
setting, mRNA measurements from more than 3200 snap 
frozen clinical tumor samples were then applied to the pro-
file. Hereby, only markers already known to be present in 
patient tumors contributed to the final profiles. The final 
signature consists of two sets of genes (158 up-regulated 
and 141 down-regulated features). The profile score was 
defined as the difference between the averages of the two 
groups of features. The scores were compared to a reference 
population of 819 breast cancer biopsies in order to obtain 
a percentile score for each patient sample.
Tissue handling
Blocks of formalin-fixed, paraffin-embedded (FFPE) tumor 
tissue were sectioned from diagnostic biopsies from pri-
mary tumor from the enrolled patients as part of the LiPla-
Cis study. mRNA from the tissue was extracted, labeled, 
and hybridized to Affymetrix GeneChip 133 plus2 arrays 
(Thermo Fisher Scientific, Waltham, MA, USA) by Medical 
Prognosis Institute.
Statistical analysis
Data were analyzed as specified in the statistical analysis 
plan. An additional supplementary analysis identifying a 
clinical cutpoint for the DRP was performed. The retrospec-
tively collected clinical data were compared to the blinded 
predictions of sensitivity and resistance. All statistical pre-
diction analyses were done blinded except for the supple-
mentary analyses. Tests for interaction between the DRP 
and prior treatment were done to assess effect of these on 
the predictive value of the DRP.
Primary endpoint was time to progression (TTP) defined 
as time from start of treatment to progression. The statisti-
cal evaluation of TTP was done using the Cox proportional 
hazards model stratifying for treatment line. Patients not 
reaching progression were censored at the last seen date. 
The DRP was the explanatory variable and was entered into 
the model as a continuous covariate scored so that the hazard 
ratio (HR) was for a 50 percentage point difference.
A clinical cutpoint estimate for the DRP score was esti-
mated assuming that the probability of progression at 6 
months be at least 25%.
A multivariate model was performed including age, estro-
gen receptor (ER) status, number of metastatic sites, and 
performance status (PS) in addition to the DRP to adjust for 
factors of prognostic relevance. In addition, an adjustment 
for the year of treatment was considered. HR for both uni- 
and multivariate analyses is presented.
Model assessment of the linearity of the DRP covariate 
and the proportional hazards assumption were done using 
martingale residuals. Cases with missing values were not 
included in the analyses. A P value of < 0.05 (one sided) 
was considered significant.
All calculations and final database management were 
done using SAS (v9.4, Cary, NC, USA).
Results
Baseline patient characteristics
A total of 140 patients received epirubicin and were included 
in the analysis. The study population was diagnosed with 
primary BC between 1986 and 2015 and received epiru-
bicin in the locally advanced or metastatic setting between 
May 1997 and November 2016. Of the 140 patients, four 
received epirubicin more than once in the metastatic set-
ting besides the 20 patients treated with epirubicin in the 
adjuvant setting.
No associations were found between the epirubicin DRP 
and any of the clinical variables (Table 1).
Treatment was changed from epirubicin to another treat-
ment due to either progression of disease (37.9%), physician 
decision (30%), toxicity (19.3%), because of long-lasting 
stable disease (3.6%), or patient decision (2.1%). Data are 
missing for ten patients. Median follow-up time was 6.2 
months (range 1.5–13.2) and 50 patients (36%) had died at 
the last follow-up.
The epirubicin gene expression profile
The Cox regression model, scoring the DRP as a continu-
ous covariate, demonstrated that the DRP was significantly 
associated to TTP (P = 0.03, one sided). Median TTP was 
9.3 months (95% confidence interval (CI) 7.2–13.2). Model 
validation did not demonstrate departures from the assump-
tions and results were not dependent on the chronological 
year of treatment (data not shown).
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Table 1  Baseline patient 
characteristics Baseline characteristics Received epirubicin in advanced setting
DRP association
N = 140 P value
Age at first relapse, years in median (Q1–Q3) 62.1 (35.8–75.2) r = 0.08a, P = 0.40
Time to relapse, years in median (Q1–Q3) 4.2 (0.0-25.2)
ER status, N (%) 0.34
 Positive 122 (87.1%)
 Negative 17 (12.1%)
 Data missing 1 (0.7%)
HER-2 status, N (%) 0.31
 Positive 16 (11.4%)
 Negative 110 (78.6%)
 Data missing 14 (10%)
Adjuvant chemotherapy, N (%)
 CMF 9 (6.4%) 0.29
 CEF 9 (6.4%) 0.84
 EC-Tax 11 (7.9%) 0.91
 Other 3 (2.1%)
 None 106 (75.7%)
 Data missing 2 (1.4%)
Adjuvant anti-hormone therapy, N (%)
 Tamoxifen 18 (12.8%) 0.23
 Tamoxifen + AI 33 (23.6%) 0.24
 AI 15 (10.7%) 0.62
 None 74 (52.8%)
 Data missing –
Adjuvant anti HER-2 directed therapy, N (%)
 Trastuzumab 5 (3.6%) 0.68
 Data missing 31 (22.1%)
Number of anti-hormone therapies prior to epirubicin, N (%)
 0 therapies 65 (46.4%)
 1 37 (26.4%)
 2 16 (11.4%)
 3 11 (7.9%)
 4 or more 11 (7.9%)
Number of chemotherapies prior to epirubicin, N (%)
 0 therapies 62 (44.3%)
 1 38 (27.1%)
 2 25 (17.9%)
 3 7 (5.0%)
 4 or more 8 (5,7%)
No. of treatment line receiving epirubicin, N (%)
 1 29 (20.7%)
 2 30 (21.4%)
 3 24 (17.1%)
 4 24 (17.1%)
 5 or more 33 (23.7%)
Performance Status at time of treatment, N (%) 0.11
 0–1 81 (57.9%)
 2 7 (5.0%)
 3 or more 2 (1.4%)
 Data missing 50 (35.7%)
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Based on the Cox regression comparing two patients with 
DRP scores differing by 50 percentage points, e.g., a DRP-
value of 75% and a DRP-value of 25%, the estimated HR 
was 0.55 (95% CI –0.93, P = 0.03, one-sided). The estimated 
median TTP for a patient with a DRP-value of 75% was 13 
months, whereas this was reduced to 7 months for patients 
with a DRP-value of 25%. This means that the difference 
between being predicted as a good responder (DRP ≥ 75%) 
versus a poor responder (DRP ≤ 25%) resulted in a difference 
in risk of progression of at least 12% at 6 months and the 
difference in median TTP was estimated to be 6 months as 
shown in Fig. 3a (blue lines).
Similarly, calculating for an 80 percentage point differ-
ence (DRP-value of 10% versus DRP-value of 90%), the 
HR was 0.39 (90% CI 0.17–0.89), demonstrating a strong 
separation in the risk between extreme DRP-values (Fig. 3b).
The Kaplan Meier survival estimates are shown in Fig. 4. 
This analysis is done with DRP dichotomized at DRP = 50% 
and has a p value of 0.01 (one sided).
The DRP predicts time to death from initiation of 
treatment with epirubicin, HR 0.48 (90% CI 0.29–0.80), 
P = 0.009 (one sided).
Multivariate analysis
The results from multivariate analysis are shown in Table 2. 
Reference age is 50–60 years (defined at start of epirubicin 
treatment), ER positive tumor, one metastasis and PS 0–1.
It is well known that ER-negative tumors exhibit a more 
aggressive biology which is reproduced here although with 
few patients. No age dependence could be demonstrated. 
Finally, the tumor burden measured as number of metas-
tases and PS were not statistically significant.
The analysis shows that only ER status is statistically 
significant in addition to the DRP.
The DRP is significant in both multi- and univariate 
analyses.
This retrospective study spans over almost 30 years. 
Including a covariate for the time from the primary diag-
nosis to the current treatment could not demonstrate a 
significant effect, P = 0.21 with the predictor remaining 
significant.
The DRP was not dependent on whether adjuvant or 
prior treatment with chemotherapy was given (Test for 
interaction, Cox regression model, P = 0.70).
A test for interaction between adjuvant or prior treat-
ment with anthracyclines and the predictor was not sig-
nificant (P = 0.69) though only 20 patients had received 
adjuvant anthracycline.
Prior taxane treatment can possibly lead to resistance to 
anthracycline treatment [21] but the interaction between 
treatment with taxanes either in the adjuvant setting or for 
advanced disease prior to the current treatment and the 
DRP was not significant in a multivariate model (P = 0.46).
Table 1  (continued) Baseline characteristics Received epirubicin 
in advanced setting
DRP association
N = 140 P value
Number of metastatic sites in line receiving epirubicin, N (%) 0.13
 1 57 (40.7%)
 2 36 (25.7%)
 3 27 (19.3%)
 4 or more 20 (14.3%)
Place of metastatic sites in line receiving epirubicin, N (%)
 Breast 21 (15.0%)
 Lymph nodes 40 (28.6%)
 Skin 9 (6.4%)
 Liver 44 (31.4%)
 Bone or marrow 76 (54.3%)
 Lung or pleura 38 (27.1%)
 CNS 2 (1.4%)
 Peritoneal 8 (5.7%)
 Other 13 (9.3%)
ER Estrogen receptor, HER-2 human epidermal growth receptor 2, CMF cyclophosphamide, methotrexate 
and 5-fluorouracil, CEF cyclophosphamide, epirubicin and 5-fluorouracil, EC-Tax: epirubicin, cyclophos-
phamide and docetaxel, AI aromatase inhibitors
a Spearman rank correlation
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Supplementary analyses
The estimated clinical cut-off for progression at 6 months 
and with at least 25% with progression was a DRP-value 
of 77%. Patients with a DRP-value less than 38% had a 
probability of more than 25% of progression at 4 months.
Discussion
We found a significant association of the continuous DRP 
with TTP in epirubicin-treated advanced BC patients. TTP 
was furthermore significantly longer in the high-DRP group 
(DRP ≥ 50) as compared to the low-DRP group.
Fig. 3  Cox regression with DRP-values of a 25 and 75% and b 10 and 90%. The gray horizontal line represents the median. In a the blue vertical 
lines point out the 6 months’ difference at median time to progression (TTP)
Fig. 4  Kaplan Meier survival plot. The gray horizontal line indicates 
median survival time
Table 2  Multivariate analysis
Parameter Hazard ratio Confidence interval P value
DRP 0.57 [0.35–0.94] 0.032
Age
 < 50 0.47 [0.19–1.17]
 50–60 1.00 (Reference) –
 60–70 0.54 [0.26–1.14]
 > 70 0.42 [0.18–0.97]
ER negatives 4.49 [2.14–9.44] 0.0004
Metastatic sites
 1 1.00 (Reference) – 0.07
 2 1.89 [0.98–3.63]
 3 0.66 [0.27–1.63]
 > 3 0.64 [0.24–1.71]
Performance status
 2 versus 0–1 2.74 [0.66–11.4] 0.36
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The DRP for epirubicin has previously been evaluated 
on published material in a neoadjuvant setting in early BC 
with statistically significant findings [17]. This present study 
validates the former findings in an advanced BC cohort.
The applicability of an anthracycline biomarker in BC, 
e.g., topoisomerase II alpha (TOP2A) has previously been 
thoroughly reviewed but has not yet been introduced into 
clinical practice [22]. Today a biomarker for specific chemo-
therapy is still highly needed [23]. In order to assist the treat-
ing physician, the biomarker has to present proper clinical 
significance. Our supplementary analysis found that patients 
with a DRP of 77% or higher had a probability of 25% of 
at least 6 months before progression occurred. Further, we 
found that patients with a DRP-value of less than 38% had a 
probability of 25% of progression at 4 months. This means 
that the DRP possibly could predict which patients would 
benefit from epirubicin less or more than 6 months in an 
advanced setting.
Our results showed that the estimated median TTP for a 
patient with a DRP of 25% was 7 months compared to 13 
months with a DRP of 75%. It could be argued that 7 months 
is not a bad result in advanced breast cancer. However, epi-
rubicin is typically used early in the advanced setting and it 
is probably one of the most effective drugs which is corrobo-
rated by the fact that it is an important part of the standard 
adjuvant chemotherapy.
Previous validation of the DRP method has been clinical 
trials with selected populations not representing the broad 
diversity of patients. This study aimed to validate the DRP 
in an intention to treat analysis with non-selected all-comers 
which included all subtypes of BC supposedly representing 
the real world.
A strength of this study is the multicenter setup with ten 
major hospitals covering Denmark ensuring a broad clini-
cal applicability, e.g., this setup did reduce the possible bias 
that different sites use epirubicin in different treatment lines.
The primary limitation to the study is the retrospective 
observational design.
Several of the included patients had their biopsy taken at 
time of primary diagnosis up to more than 20 years before 
our assays were done. These old biopsies were pooled with 
biopsies from patients diagnosed more recently resulting 
in a median age of biopsies of 10 years. However, date of 
biopsy did not affect prediction demonstrating that a fragile 
molecule like RNA can be extracted and measured more 
than a decade after biopsy. Biochemistry from FFPE tis-
sue is notoriously difficult; however, methods are steadily 
improving and FFPE tissue may be a very valuable source 
of information in the future. To prevent possible bias from 
patients’ prior treatments such as taxane, in future studies it 
should be preferred to use new biopsies if possible instead 
of biopsies taken by primary diagnosis in case of long time 
gap between primary cancer and advanced disease.
The results from this study are remarkable and future 
studies predicting anthracycline response also as (neo)adju-
vant therapy could be of interest. The DRP used in this set-
ting could support the decision of potentially curable treat-
ment compared to the palliative focus of this study.
The result from this study is clinically meaningful but 
could be further strengthened by a prospective study in a 
randomized setting between physician treatment decision 
and the DRP to demonstrate if such an approach will lead to 
increased overall survival. A prospective study with liposo-
mal doxorubicin is already initiated using this technology in 
collaboration with DBCG.
In conclusion, this validation of the DRP showed signifi-
cant prediction of response to anthracyclines in advanced 
BC. The DRP can support the clinician with a better-
informed treatment decision for anthracyclines in advanced 
BC. In addition, the DRP can assist in development of more 
accurate treatment, prevent ineffective cytotoxic effects, and 
potentially impact patient survival.
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